Stock ABVX ABIVAX
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Abivax

Equities

ABVX

FR0012333284

Market Closed - Euronext Paris
Other stock markets
 11:35:05 2024-07-12 am EDT 		5-day change 1st Jan Change
12.7 EUR +1.28% Intraday chart for Abivax +1.93% +29.33%
May. 20 BTIG Initiates Abivax at Buy Rating With $43 Price Target MT
May. 08 Abivax: four abstracts to be presented on obefazimod CF

Evolution of the average Target Price on Abivax

Price target over the last 5 years

History of analyst recommendation changes

fec33e98da5d.y1hLbHVlQ2_SF3osChbWoxdfElkYOvYm749JtuUrQhk.qSAkMyYGdSyCbwxZPE_my3hmRhx_cqd3muYb-4d0c0OcMxobJBMTPbZ8HQ~e00ef23f3ef2d92915a0d2fcc750f394

Analyst Recommendations on Abivax

BTIG Initiates Abivax at Buy Rating With $43 Price Target MT
Abivax: share price rises as two analysts express optimism CF
Piper Sandler Starts Abivax With Overweight Rating, $42 Price Target MT
Guggenheim Starts Abivax With Buy Rating, $50 Price Target MT
Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating MT
Abivax: in green, broker in support CF
ABIVAX : Oddo BHF maintains its outperform rating CF
Valneva: up sharply after positive analysis CF
ABIVAX : Portzamparc downgrades its recommendation CF
Abivax: no trend after unsurprising results CF
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.7 EUR
Average target price
36.34 EUR
Spread / Average Target
+186.14%
High Price Target
65 EUR
Spread / Highest target
+411.81%
Low Price Target
17.7 EUR
Spread / Lowest Target
+39.37%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Abivax

BTIG
Guggenheim
Piper Sandler
Morgan Stanley

Ratings for Abivax

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ABVX Stock
  4. Consensus Abivax